SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced the approval of new inducement awards by the Compensation Committee of its Board of Directors on June 6, 2025. Under Acadia's 2024 Inducement Plan, 41 new employees have been granted non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (RSUs). The stock options have an exercise price of $21.98 per share, aligned with the closing trading price on the grant date, and are set to vest over four years. The RSUs will also vest over a four-year period, with 50% vesting on the second anniversary of the grant date. These awards are contingent upon the employees' continued service with Acadia and are governed by the terms of the 2024 Inducement Plan and corresponding award agreements.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。